Journey Medical Corp (NASDAQ:DERM) is one of the best performing micro cap stocks in 2025. Lake Street analyst Thomas Flaten reaffirmed a Buy rating on DERM with a $13 price target. Earlier, Journey Medical published positive Phase 1 Emrosi microbiome data in the Journal of Drugs in Dermatology.

The Phase 1 trial showed no significant microbiome changes in skin, no notable antibiotic resistance to minocycline, and no major rise in opportunistic organisms compared to placebo. Emrosi is well tolerated with a low-dose profile to minimize disruption to normal body flora, supporting safe use in rosacea patients.

Emrosi, an FDA-approved oral medication for skin conditions, received approval in November 2024. It is the only oral therapy for inflammatory lesions and redness in rosacea, backed by Phase 3 clinical trials in the US and Germany. Journey Medical Corp focuses on developing and marketing prescription dermatology products.

While DERM shows investment potential, certain AI stocks offer greater upside with less risk. For an undervalued AI stock benefiting from Trump-era tariffs and onshoring trends, check out the best short-term AI stock. Explore 10 Must-Buy AI Stocks to Invest In and 11 Best NYSE Stocks Under $5 to Buy for more investment opportunities.

Read more at Yahoo Finance: Journey Medical (DERM) Publishes Positive Emrosi Phase 1 Microbiome Data